-
1.
公开(公告)号:US20240174612A1
公开(公告)日:2024-05-30
申请号:US18386724
申请日:2023-11-03
Applicant: VIRGINIA COMMONWEALTH UNIVERSITY , IllExcor Therapeutics, LLC , KING ABDULAZIZ UNIVERSITY , CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)
Inventor: Martin SAFO , Yan ZHANG , Andrew FLEISCHMAN , David LIGHT , Moustafa EL-ARABY , Abdelsattar OMAR , Osheiza ABDULMALIK
IPC: C07D213/30 , A61P7/06 , C07D239/26
CPC classification number: C07D213/30 , A61P7/06 , C07D239/26
Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
-
2.
公开(公告)号:US20240109843A1
公开(公告)日:2024-04-04
申请号:US18501244
申请日:2023-11-03
Applicant: VIRGINIA COMMONWEALTH UNIVERSITY , KING ABDULAZIZ UNIVERSITY , THE CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP) , IllExcor Therapeutics, LLC
Inventor: Martin SAFO , Yan ZHANG , Piyusha Pradeep PAGARE , Guoyan XU , Mohini GHATGE , Jurgen VENITZ , Osheiza ABDULMALIK , Andrew FLEISCHMAN , David LIGHT , Moustafa EL-ARABY , Abdelsattar OMAR
IPC: C07D213/80 , A61K9/00 , A61P7/00 , C07D213/79 , C07D401/04 , C07D409/04
CPC classification number: C07D213/80 , A61K9/0053 , A61P7/00 , C07D213/79 , C07D401/04 , C07D409/04
Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
-
3.
公开(公告)号:US20250019349A1
公开(公告)日:2025-01-16
申请号:US18767363
申请日:2024-07-09
Applicant: VIRGINIA COMMONWEALTH UNIVERSITY , IllExcor Therapeutics, LLC , KING ABDULAZIZ UNIVERSITY , CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP)
Inventor: Martin SAFO , Yan ZHANG , Andrew FLEISCHMAN , David LIGHT , Moustafa EL-ARABY , Abdelsattar OMAR , Osheiza ABDULMALIK
IPC: C07D213/30 , A61P7/06 , C07D239/26
Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
-
公开(公告)号:US20190256483A1
公开(公告)日:2019-08-22
申请号:US16318590
申请日:2017-07-24
Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
Inventor: Martin K. SAFO , Guoyan XU , Yan ZHANG , Osheiza ABDULMALIK
IPC: C07D307/46 , C07F9/655 , A61P7/00 , A61P43/00
Abstract: Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.
-
公开(公告)号:US20220340531A1
公开(公告)日:2022-10-27
申请号:US17846101
申请日:2022-06-22
Inventor: Martin K. SAFO , Yan ZHANG , Piyusha Pradeep PAGARE , Guoyan XU , Mohini GHATGE , Jurgen VENITZ , Osheiza ABDULMALIK
IPC: C07D213/80 , A61P7/00 , A61K9/00 , C07D213/79 , C07D401/04 , C07D409/04
Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
-
公开(公告)号:US20210002225A1
公开(公告)日:2021-01-07
申请号:US16982745
申请日:2019-03-18
Inventor: Martin K. SAFO , Yan ZHANG , Piyusha Pradeep PARAGE , Guoyan XU , Mohini GHATGE , Jurgen VENITZ , Osheiza ABDULMALIK
IPC: C07D213/80 , C07D213/79 , C07D401/04 , C07D409/04 , A61K9/00 , A61P7/00
Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
-
-
-
-
-